Innovative Clinical Tools Elucid's advanced, histology-validated software provides physicians with precise, non-invasive analysis of atherosclerotic plaque characteristics, creating opportunities to target cardiovascular care providers seeking tools to improve treatment accuracy and patient outcomes.

Growing Market Presence With recent participation in prominent industry events like SCCT 2025 and strategic hires such as new board members and medical leadership, Elucid is expanding its visibility and credibility within the cardiovascular imaging and medical technology sectors.

Funding and Growth Backed by $80 million in funding and generating up to $25 million in revenue, Elucid is positioned for strategic expansion and product development, offering potential sales avenues for partners interested in innovative imaging software.

Advanced Technology Usage Utilizing a tech stack that includes Google Cloud, OpenAI, and iOS, Elucid demonstrates strong commitment to leveraging cutting-edge technology, appealing to healthcare providers and enterprise customers looking for scalable, AI-driven solutions.

Market Differentiation As the first non-invasive software capable of quantifying complex plaque features akin to histopathology, Elucid offers a differentiated value proposition that can be marketed to cardiology and radiology specialties aiming for precision medicine and cost-effective diagnostic options.